ConductScience.org, home
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
API referenceFor AI assistants

Trial · NCT04773587

Results by group22

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 22

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4Roflumilast Cream 0.15%32.095% Confidence Interval 27.79 to 36.63percentage of participants
Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4Vehicle Cream15.295% Confidence Interval 11.06 to 20.64percentage of participants
Achievement of vIGA-AD Success at Week 4 in Participants With Moderate Baseline ScoresRoflumilast Cream 0.15%35.095% Confidence Interval 29.97 to 40.36percentage of participants
Achievement of vIGA-AD Success at Week 4 in Participants With Moderate Baseline ScoresVehicle Cream17.595% Confidence Interval 12.38 to 24.13percentage of participants
Achievement of a 4-Point Reduction in the Average, Weekly Worst Itch Numeric Rating Scale (WI-NRS) at Week 4 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4Roflumilast Cream 0.15%33.695% Confidence Interval 28.19 to 39.41percentage of participants
Achievement of a 4-Point Reduction in the Average, Weekly Worst Itch Numeric Rating Scale (WI-NRS) at Week 4 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4Vehicle Cream20.795% Confidence Interval 14.61 to 28.58percentage of participants
Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 2 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4Roflumilast Cream 0.15%23.895% Confidence Interval 19.14 to 29.24percentage of participants
Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 2 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4Vehicle Cream9.895% Confidence Interval 5.79 to 16.03percentage of participants
Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 1 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4Roflumilast Cream 0.15%9.595% Confidence Interval 6.60 to 13.60percentage of participants
Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 1 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4Vehicle Cream2.395% Confidence Interval 0.77 to 6.41percentage of participants
Achievement of ≥ 75% Reduction in the Eczema Area and Severity Index (EASI-75) at Week 4Roflumilast Cream 0.15%43.295% Confidence Interval 38.54 to 47.94percentage of participants
Achievement of ≥ 75% Reduction in the Eczema Area and Severity Index (EASI-75) at Week 4Vehicle Cream22.095% Confidence Interval 16.97 to 28.04percentage of participants
Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 4Roflumilast Cream 0.15%41.595% Confidence Interval 36.93 to 46.25percentage of participants
Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 4Vehicle Cream25.295% Confidence Interval 19.91 to 31.41percentage of participants
Achievement of vIGA-AD Success at Week 2Roflumilast Cream 0.15%21.295% Confidence Interval 17.57 to 25.33percentage of participants
Achievement of vIGA-AD Success at Week 2Vehicle Cream6.495% Confidence Interval 3.84 to 10.44percentage of participants
Achievement of vIGA-AD Success at Week 1Roflumilast Cream 0.15%8.195% Confidence Interval 5.87 to 11.03percentage of participants
Achievement of vIGA-AD Success at Week 1Vehicle Cream0.595% Confidence Interval 0.08 to 2.52percentage of participants
Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 2Roflumilast Cream 0.15%31.895% Confidence Interval 27.58 to 36.38percentage of participants
Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 2Vehicle Cream13.695% Confidence Interval 9.72 to 18.79percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04773587/results

API referenceFor AI assistants